Skip to main content
SpringerLink
Log in

Anti-tumor action and clinical application of proteasome inhibitor

  • Review
  • Published:
Chinese Journal of Cancer Research

Abstract

Ubiquitin-proteasome pathway mediates the degradation of cell protein, and cell cycle, gene translation and expression, antigen presentation and inflammatory development. Proteasome inhibitor can inhibit growth and proliferation of tumor cell, induce apoptosis and reverse multipledrug resistance of tumor cell, increase the sensitivity of other chemotherapeutic drugs and radiotherapy, and is a novel class of potent anti-tumor agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Voorhees PM, Dees EC, O’Neil B, et al. The proteasome as a target for cancer therapy[J]. Clin Cancer Res 2003; 9:6316–6325.

    PubMed  CAS  Google Scholar 

  2. Tao GZ, Rott LS, Lowe AW, et al. Hyposmotic stress induces cell growth arrest via proteasome activation and cyclin/cyclin-dependent kinase degradation[J]. J Biol Chem 2002; 277: 19295–19303.

    Article  PubMed  CAS  Google Scholar 

  3. Xu J, Attisano L. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting smads to ubiquitin-proteasome pathway[J]. Proc Natl Acad Sci USA 2000; 97: 4820–4825.

    Article  PubMed  CAS  Google Scholar 

  4. Ogiso Y, Tomida A, Kim HD, et al. Glucose starvation and Hypoxia induce nuclear accumulation of proteasome in cancer cells[J]. Biochem Biophys Res Commun 1999; 258: 448–452.

    Article  PubMed  CAS  Google Scholar 

  5. Aghajanian C, Soigent S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies[J]. Clin Cancer Res 2002; 8: 2505–2511.

    PubMed  CAS  Google Scholar 

  6. Sakata N, Dixon JL. Ubiquitin-proteasome-dependent degradation of apolipoprotein B100 in vitro[J]. Biochem Biophys Acta 1999; 1437: 71–79.

    PubMed  CAS  Google Scholar 

  7. Koguchi Y, Kohno J, Nishio M, et al. Tmc-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC1093. Taxonomy, production, isolation, and biological activities[J]. J Antibiot 2000; 53: 105–109.

    PubMed  CAS  Google Scholar 

  8. Kazi A, Daniel KG, Smith DM, et al. Inhibition of proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein[J]. Biochem Pharmacol 2003; 66: 965–976.

    Article  PubMed  CAS  Google Scholar 

  9. Adams J. Development of the proteasome inhibitor PS-341[J]. Oncologist 2002; 7: 9–16.

    Article  PubMed  CAS  Google Scholar 

  10. Leblanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model[J]. Cancer Res 2002; 62: 4996–5000.

    PubMed  CAS  Google Scholar 

  11. Mitchell BS. The proteasome-an emerging therapeutic target in cancer[J]. N Engl J Med 2003; 348: 2597–2598.

    Article  PubMed  Google Scholar 

  12. Hochwald SN, Lind DS, Malaty J, et al. Antincoplastic therapy in colorectal cancer through proteasome inhibition[J]. Am Surg 2003; 69:15–23.

    PubMed  Google Scholar 

  13. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibtiors: a novel class of potent and effective antitumor agents[J]. Cancer Res 1999; 59: 2615–2622.

    PubMed  CAS  Google Scholar 

  14. Cusack JC Jr, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341:Implication for systemic nuclear factor-KB inhibitor[J]. Cancer Res 2001; 61: 3535–3540.

    PubMed  CAS  Google Scholar 

  15. Fan XM, Wong BC, Wang WP, et al. Inhibition of proteasome function induced apoptosis in gastric cancer[J]. Int J Cancer 2001; 93: 481–488.

    Article  PubMed  CAS  Google Scholar 

  16. Chen F, Chang D, Goh M, et al. Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors[J]. Cell Growth Differ 2000; 11: 239–246.

    PubMed  CAS  Google Scholar 

  17. Fukuchi K, Hagiwara T, Nakamura K, et al. Identification of the regulatory region required for ubiquitination of the cyclin kinase inhibitor, p21[J]. Biochem Biophys Res Commun 2002; 293: 120–125.

    Article  PubMed  CAS  Google Scholar 

  18. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells[J]. Proc Natl Acad Sci USA 2002; 99: 14374–14379.

    Article  PubMed  CAS  Google Scholar 

  19. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade(Bortezomib) [J]. Cancer Invest 2004; 22:304–311.

    Article  PubMed  CAS  Google Scholar 

  20. Esparis-Ogando A, Alegre A, Aguado B, et al. Bortezomib is an efficient agent in plasma cell leukemias[J]. Int J Cancer 2005; 114: 665–667.

    Article  PubMed  CAS  Google Scholar 

  21. Loo TW, Clarke DM. The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy [J]. FASEB J 1999; 13: 1724–1732.

    PubMed  CAS  Google Scholar 

  22. Loo TW, Clarke DM. Superfolding of the partially unfolded Core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions [J]. J Biol Chem 1998; 273: 14671–14674.

    Article  PubMed  CAS  Google Scholar 

  23. Kim OH, Lim JH, Woo KJ, et al. Inference of p53 and p21WAF1 expression on G2/M phase arrest of colorectal carcinoma HCT 116 cells to proteasome inhibitors[J]. Int J Oncol 2004; 24: 935–941.

    PubMed  CAS  Google Scholar 

  24. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells[J]. Cancer Res 2001; 61: 3071–3076.

    PubMed  CAS  Google Scholar 

  25. An WG, Hwang SG, Trepel JB, et al. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition[J]. Leukemia 2000; 14: 1276–1283.

    Article  PubMed  CAS  Google Scholar 

  26. Frankel A, Man S, Elliott P, et al. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341[J]. Clin Cancer Res 2000; 6:3719–3728.

    PubMed  CAS  Google Scholar 

  27. Yunmbam MK, Li QQ, Mimnaugh EG, et al. Effect of the proteasome inhibitor ALLnL on cisplatin sensitivity in human ovarian tumor cells[J]. Int J Oncol 2001; 19: 741–748.

    PubMed  CAS  Google Scholar 

  28. Fujita T, Washio K, Takabatake D, et al. Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance[J]. Int J Cancer 2005; 117: 670–682.

    Article  PubMed  CAS  Google Scholar 

  29. Lin ZP, Boller YC, Amer SM, et al. Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: involvement of NF-κB activation in drug resistance[J]. Cancer Res 1998; 58: 3059–3065.

    PubMed  CAS  Google Scholar 

  30. Pahl HL, Baeuerle PA. The ER-overload response: activation of NF-κB[J]. Trends Biochem Sci 1997; 22: 63–67.

    Article  PubMed  CAS  Google Scholar 

  31. Denlinger CE, Rundall BK, Keller MD, et al. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis[J]. Ann Thorac Surg 2004; 78: 1207–1214.

    Article  PubMed  Google Scholar 

  32. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies[J]. Blood 2005; 105:3058–3065.

    Article  PubMed  CAS  Google Scholar 

  33. Richardson PG, Barlogie B, Berenson J, et al. A phase II study of bortezomib in relapsed, refractory myeloma[J]. N Engl J Med 2003; 348: 2609–2617.

    Article  PubMed  CAS  Google Scholar 

  34. Richardson PG, Barlogie B, Berenson J, et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial[J]. Cancer 2006; 106:1316–1319.

    Article  PubMed  CAS  Google Scholar 

  35. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refractory Waldenstrom’s macroglobulinemia with bortezomib [J]. Haematologica 2005; 90: 1655–1658.

    PubMed  CAS  Google Scholar 

  36. Kondagunta GV, Drucker B, Schwartz L, et al. Phase II clinical study of bortezomib for patients with advanced renal cell carcinoma[J]. J Clin Oncol 2004; 22: 3720–3725.

    Article  PubMed  CAS  Google Scholar 

  37. Alberts SR, Foster NR, Morton RF, Kugler J, Schaefer P, Wiesenfeld M, Fitch TR, Steen P, Kim GP, Gill S. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study[J]. Ann Oncol 2005; 16: 1654–1661.

    Article  PubMed  CAS  Google Scholar 

  38. Ciolli S, Leoni F, Gigli F, et al. Low dose velcade, thalidomide and dexamethasone (LD-VTD): An effective regimen for relapsed and refractory multiple myeloma patients[J]. Leuk Lymphoma 2006; 47: 171–173.

    Article  PubMed  CAS  Google Scholar 

  39. Berenson JR, Yang HH, Sadler K, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma[J]. J Clin Oncol 2006; 24: 937–944.

    Article  PubMed  CAS  Google Scholar 

  40. Hollmig K, Stove J, Talamo G, et al. Addition of bortezomib(Velcade) to high dose melphalan (Vel-Mel) as an effective conditioning regimen with autologous stem cell support in multiple myeloma (MM)[J]. Blood 2004; 104: 266a.

    Google Scholar 

  41. Harousseau JL, Attal M, Leleu X, et al. Bortezomib (Velcade) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Preliminary results of an IFM phase II study[J]. Blood 2004; 104: 416a.

    Google Scholar 

  42. Rosinol L, Montoto S, Ciberira MT, et al. Bortezomib-induced severe hepatitis in multiple myeloma: a case report[J]. Arch Intern Med 2005; 165: 464–465.

    Article  PubMed  Google Scholar 

  43. Engelhardt M, Muller AM, Maier W, et al. Severe irreversible bilateral hearing loss after Bortezomib (Velcade) therapy in a multiple myeloma(MM) patient[J]. Leukemia 2005; 19: 869–870.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of hematology, The Affiliated Hospital, Wuhan University of Science and Technology, Wuhan, 430000, China

    Yong-ming Zhou  (周咏明), Mei-xia Yu  (余美霞) & Hui Long  (龙辉)

  2. Stem Cell Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

    Shi-ang Huang  (黄士昂)

Authors
  1. Yong-ming Zhou  (周咏明)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mei-xia Yu  (余美霞)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hui Long  (龙辉)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shi-ang Huang  (黄士昂)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shi-ang Huang  (黄士昂).

Additional information

This work was supported by the National Outstanding Youth Scientists Foundation of china (No. 30225038) and the Youth and Middle-Age Scientists Science and Research Found of the Affiliated Hospital, Wuhan University of Science and Technology.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhou, Ym., Yu, Mx., Long, H. et al. Anti-tumor action and clinical application of proteasome inhibitor. Chin. J. Cancer Res. 20, 77–84 (2008). https://doi.org/10.1007/s11670-008-0077-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11670-008-0077-1

Key words

CLC number

Search

Navigation